Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13429399 | 1.00 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2TSHRNPSR1CYP19A1 | |
| SCHEMBL8356702 | 1.00 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2TSHRNPSR1CYP19A1 | |
| SCHEMBL10707153 | 0.92 | ALDH1A1 (0.30) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL10486149 | 0.92 | ALDH1A1 (0.30) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL10486145 | 0.92 | ALDH1A1 (0.30) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL3935881 | 0.88 | — | — | |
| SCHEMBL12855787 | 0.87 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL184319 | 0.87 | — | — | |
| SCHEMBL20664256 | 0.86 | — | — | |
| SCHEMBL20664323 | 0.86 | HCRTR2 (0.33) | HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4497815-A | 1-(N-Substituted carbamoyl)-5-fluorouracil derivatives and the carcinostatic agents containing same as active ingredients | Ozaki, Shoichiro (JP) | 1985-02-05 | — | — | US | claimed |
| US-20230303555-A1 | PYRIMID-2-YL-PYRAZOLE COMPOUNDS AS IRAK INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2023064366-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2022048684-A1 | JNK INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉朗来科技发展有限公司 | 2022-03-10 | — | — | WO | disclosed |
| US-10696666-B2 | Pharmaceutical compounds | CellCentric Limited (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20180111923-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. | 2018-04-26 | — | — | US | disclosed |
| WO-2018073587-A1 | PHARMACEUTICAL COMPOUNDS | CELLCENTRIC LTD (GB) | 2018-04-26 | — | — | WO | disclosed |
| EP-2970155-B1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) | BRISTOL MYERS SQUIBB CO (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9904172-B2 | Shrink material and pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2018-02-27 | — | — | US | disclosed |
| US-20090028818-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2009-01-29 | — | — | US | disclosed |
| WO-2009013171-A2 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| WO-2008119663-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20080249087-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-10-09 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| US-4497815-A | 1-(N-Substituted carbamoyl)-5-fluorouracil derivatives and the carcinostatic agents containing same as active ingredients | Ozaki, Shoichiro (JP) | 1985-02-05 | — | — | US | disclosed |
| US-4497815-A | 1-(N-Substituted carbamoyl)-5-fluorouracil derivatives and the carcinostatic agents containing same as active ingredients | Ozaki, Shoichiro (JP) | 1985-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | ALDH1A1 135/4885SMN1; SMN2 877/4885TSHR 3678/4885 |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | GSK3A, CDK11A, CDK1 | ALDH1A1 1576/4885SMN1; SMN2 3655/4885TSHR 866/4885 |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | ALDH1A1 2661/4885SMN1; SMN2 536/4885TSHR 3111/4885 |
| US-20180111923-A1 | IRAK INHIBITORS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | ALDH1A1 1451/4885SMN1; SMN2 1182/4885TSHR 4127/4885 |
| US-20090028818-A1 | Heterocyclic antiviral compounds | CCR5, CCR1, CCR2 | ALDH1A1 622/4885SMN1; SMN2 3036/4885TSHR 577/4885 |
| US-20230303555-A1 | PYRIMID-2-YL-PYRAZOLE COMPOUNDS AS IRAK INHIBITORS | IRAK2, IRAK3, IRAK1 | ALDH1A1 1493/4885SMN1; SMN2 1685/4885TSHR 3535/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | ALDH1A1 2369/4885SMN1; SMN2 3286/4885TSHR 4691/4885 |
| US-20080249087-A1 | Heterocylic antiviral compounds | CCR5, CCR1, CXCR1 | ALDH1A1 339/4885SMN1; SMN2 3620/4885TSHR 1007/4885 |
| US-10696666-B2 | Pharmaceutical compounds | EP300, HDAC1, HDAC11 | ALDH1A1 768/4885SMN1; SMN2 3831/4885TSHR 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.